Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Clinical & Translational Science Institute / Stories / August 2020 / COVID-19 Biobank Now Open for Business

COVID-19 Biobank Now Open for Business

The COVID-19 Biobank, which was announced by the University of Rochester Clinical & Translational Science Institute at the beginning of June, is now ready for researchers to use.

The Biobank, which was created through a partnership between the UR CTSI and the Shared Resource Labs at the University of Rochester Medical Center, has collected samples from 157 unique donors, 110 of whom had PCR-confirmed COVID-19 diagnoses. Thanks to those donors, URMC researchers can now apply for access to nearly 4,200 vials of serum, 30 vials of plasma and 30 vials of peripheral blood mononuclear cells (PBMC) – and these numbers are ever-growing.COVID-19 Biobank Dashboard snapshot as of 8/4/20, 9:36 am.

For a near-real-time overview of donors and samples, visit the COVID-19 Biobank dashboard. Before requesting access, researchers can see if the Biobank will meet their needs by filtering the dashboard results by sample type (serum, plasma or cells), COVID-19 status, donor age and sample volume.

The serum samples, which are leftover from specimens collected from hospitalized patients for COVID-19 tests, are supplied by the Department of Pathology and Laboratory Medicine. Plasma and PBMC samples are being collected from consented inpatients at three approximate time points (close to admission, three to five days after the first draw and eight to 10 days after the first draw) under a longitudinal, prospective study.

University of Rochester research faculty and staff can request access to samples and associated de-identified clinical data (like diagnoses, labs, medications, etc.) by filling out the UR CTSI Informatics Service Request form. These requests should be made prior to submitting an RSRB protocol for a COVID-19 study. Research proposals that plan to use specimens collected as part of the COVID19 Biobank should be submitted via the university’s central study interest form.

Requests are reviewed weekly and are evaluated based on the availability of the requested samples, significance and feasibility of the study’s aims, expertise of the study team and PI, funding and the value of the proposed research to the Rochester community.  

Learn more about how to use the COVID-19 Biobank and contact if you have any questions.


Startup funding for the Biobank was supplied in part by the Harry T. Mangurian, Jr. Foundation and the University of Rochester Clinical and Translational Science Award (UL1 TR002001).

Susanne Pritchard Pallo | 8/4/2020

You may also like